[HTML][HTML] The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality
worldwide. The emergence of combination therapy, atezolizumab (anti-PDL1, immune …
worldwide. The emergence of combination therapy, atezolizumab (anti-PDL1, immune …
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Y Pang, N Ghosh - Frontiers in Oncology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
Enhancing antitumor response by efficiently generating large-scale TCR-T cells targeting a single epitope across multiple cancer antigens
OB Amissah, R Basnet, W Chen… - Cellular …, 2024 - Elsevier
The need to contrive interventions to curb the rise in cancer incidence and mortality is critical
for improving patients' prognoses. Adoptive cell therapy is challenged with quality large …
for improving patients' prognoses. Adoptive cell therapy is challenged with quality large …